BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Lupus (SLE / lupus nephritis) clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for systemic lupus erythematosus: 208 (116 sponsors; 28 newly posted in the last 180 days, 10 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 12.3, rank 55 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 11, Phase 1 77, Phase 2 62, Phase 3 35, Phase 4 4, N/A 19.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 24 | NA 12, P3 6, P1 3, P2 2, P4 1 | 4 | 3 |
| Novartis Pharmaceuticals NVS | 9 | P1 2, P3 5, P2 2 | 1 | 2 |
| Biogen BIIB | 5 | P3 5 | 0 | 0 |
| Viatris Innovation GmbH VTRS | 4 | P3 4 | 0 | 2 |
| Bristol-Myers Squibb BMY | 6 | P3 3, P1 1, P4 1, NA 1 | 2 | 0 |
| EMD Serono Research & Development Institute, Inc. | 3 | P3 3 | 1 | 0 |
| Hoffmann-La Roche | 5 | P1 1, P3 2, P2 2 | 0 | 0 |
| UCB Biopharma SRL | 3 | P3 2, P1 1 | 1 | 0 |
| AbbVie ABBV | 3 | P3 1, P1 2 | 1 | 1 |
| Qilu Pharmaceutical Co., Ltd. | 3 | P1 2, P3 1 | 1 | 1 |
| Beeline Medicines Corporation BLNE | 2 | P2 1, P3 1 | 1 | 0 |
| Beijing Mabworks Biotech Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Janssen Research & Development, LLC | 1 | P3 1 | 0 | 0 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 6 | P1 5, NA 1 | 0 | 2 |
| GlaxoSmithKline | 5 | P1 2, P2 1, NA 1, P4 1 | 0 | 0 |
| Chongqing Precision Biotech Co., Ltd | 4 | P1 4 | 0 | 0 |
| CytoCares Inc | 3 | P1 1, EARLY_P1 2 | 0 | 0 |
| Fate Therapeutics FATE | 3 | P2 2, P1 1 | 1 | 0 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 3 | P1 2, P2 1 | 0 | 0 |
| Miltenyi Biomedicine GmbH | 3 | P2 2, P1 1 | 0 | 0 |
| Autolus Limited AUTL | 2 | P2 1, P1 1 | 0 | 0 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | 2 | EARLY_P1 1, P1 1 | 0 | 0 |
| Cartesian Therapeutics RNAC | 2 | P2 2 | 0 | 1 |
| Chengdu Ucello Biotechnology Co., Ltd. | 2 | EARLY_P1 2 | 0 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2 | P2 2 | 0 | 1 |
Recently stopped trials
- NCT05268289 Novartis Pharmaceuticals - terminated: The decision to conclude the study after Part 1 LPLV is based on strategic considerations by the Sponsor. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- NCT05504187 Kira Pharmacenticals (US), LLC. - withdrawn: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Sec
- NCT06943937 China Immunotech (Beijing) Biotechnology Co., Ltd. - terminated: Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
- NCT07083349 Base Therapeutics (Shanghai) Co., Ltd. - terminated: poor accrual NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus
- NCT05938725 Kyverna Therapeutics - terminated: Study discontinued due to sponsor decision. KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Ne
- NCT06342960 Kyverna Therapeutics - terminated: Study discontinued due to sponsor decision. KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Ne
- NCT05879718 Pfizer - terminated: Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect re A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.
- NCT06161116 Merck Sharp & Dohme LLC - terminated: Business Reasons Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
- NCT06984341 Genentech, Inc. - withdrawn: Decision of Sponsor. A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P
- NCT06935474 AbelZeta Inc. - withdrawn: Sponsor decision to discontinue development and pursue an alternative clinical development strategy C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06859931 Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | not yet recruiting | 120 |
| 2026-12 est. | P2 | Ventus Therapeutics U.S., Inc. | NCT07260877 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult | Cutaneous Lupus Erythematosus (CLE); Systemic Lupus Erythematosus; SLE; SLE (Systemic Lupus); CLE | active not recruiting | 24 |
| 2026-12-01 est. | P2 | Cartesian Therapeutics RNAC | NCT06038474 Descartes-08 for Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus (SLE) | active not recruiting | 6 |
| 2026-12-31 est. | P3 | Viatris Innovation GmbH VTRS | NCT05672576 A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | active not recruiting | 451 |
| 2027-01 est. | P2 | Shanghai Henlius Biotech | NCT07038382 A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in P | Membranous Nephropathy; Lupus Nephritis (LN) | recruiting | 24 |
| 2027-02-01 est. | P1/P2 | Gracell Biotechnologies (Shanghai) Co., Ltd. | NCT06530849 A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | Refractory Systemic Lupus Erythematosus | active not recruiting | 20 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-02 | P3 | AstraZeneca AZN | NCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus | active not recruiting | 339 |
| 2026-10-20 est. | P2/P3 | Biogen BIIB | NCT05531565 A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | active not recruiting | 450 |
| 2026-10-19 est. | P3 | Bristol-Myers Squibb BMY | NCT05620407 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 513 |
| 2026-10-19 est. | P3 | Bristol-Myers Squibb BMY | NCT05617677 A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | active not recruiting | 516 |
| 2026-10 est. | P2 | Immunovant Sciences GmbH IMVT | NCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | active not recruiting | 56 |
| 2026-10 est. | P2 | Keymed Biosciences Co.Ltd | NCT06791772 Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) | Systemic Lupus Erythematosus | not yet recruiting | 150 |
| 2026-09-30 est. | P3 | Biogen BIIB | NCT04895241 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythe | Lupus Erythematosus, Systemic | active not recruiting | 548 |
| 2026-09-27 est. | P3 | Biogen BIIB | NCT04961567 A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythe | Lupus Erythematosus, Systemic | active not recruiting | 562 |
| 2026-09-24 | P1/P2 | Novartis Pharmaceuticals NVS | NCT05798117 An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus; Lupus Nephritis | completed | 21 |
| 2026-09-23 | P2 | Zenas BioPharma (USA), LLC ZBIO | NCT06559163 A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 190 |
| 2026-09-04 | P2 | Sanofi SNY | NCT05039840 Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 109 |
| 2026-06-12 | P2 | Beeline Medicines Corporation BLNE | NCT04895696 A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | active not recruiting | 248 |
| 2026-06-08 | P1/P2 | Nanjing Immunophage Biotech Co., Ltd | NCT06717815 Phase IIa Study for IPG11406 in Patients With Lupus Nephritis | Lupus Nephritis | completed | 24 |
| 2026-05-31 est. | P1/P2 | Miltenyi Biomedicine GmbH | NCT06347718 CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | Systemic Lupus Erythematosus; Systemic Sclerosis; Dermatomyositis; Polymyositis | recruiting | 24 |
| 2026-05-29 | P1/P2 | Kyverna Therapeutics KYTX | NCT05938725 KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | Lupus Nephritis; Lupus Nephritis - World Health Organization (WHO) Class III; Lupus Nephritis - WHO | terminated | 6 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "systemic lupus erythematosus"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.